Polyclonal free light chains: a biomarker of inflammatory disease or treatment target?
Polyclonal free light chains: a biomarker of inflammatory disease or treatment target?
复制标题
多克隆游离光链：炎症性疾病或治疗靶标的生物标志物？
DOI：
10.3410/m5-4
复制
发表时间：
2013
期刊：
影响因子：
--
通讯作者：
Stockley RA
中科院分区：
文献类型：
--
作者：
Brebner JA;Stockley RA
游离轻链是由B淋巴细胞在抗体合成过程中产生的蛋白质。它们的产生，作为B细胞活化的反映，可以深入了解适应性免疫系统的活性。近年来，已经开发了提供血清中游离轻链的定量测量的自动化免疫测定。该测定不仅彻底改变了浆细胞疾病中单克隆轻链过度产生的研究，而且还允许定量血清中的多克隆游离轻链。在许多炎性和自身免疫性疾病中发现高水平的多克隆游离轻链，这导致了对其作为疾病活性生物标志物的价值的研究。对它们的生物活性的研究也突出了它们在炎症性疾病发病机制中的潜在作用，使它们成为新疗法的有吸引力的靶点。
Free light chains are proteins produced by B lymphocytes during the process of antibody synthesis. Their production, as a reflection of B cell activation, can give insight into the activity of the adaptive immune system. In recent years, an automated immunoassay that provides quantitative measurement of free light chains in the serum has been developed. This assay has not only revolutionised the investigation of monoclonal light chain overproduction in plasma cell diseases, but has also allowed for the quantification of polyclonal free light chains in serum. The discovery of high levels of polyclonal free light chains in a number of inflammatory and auto-immune conditions has led to the examination of their value as a biomarker of disease activity. Research into their bio-activity has also highlighted their potential role in the pathogenesis of inflammatory disease, making them an attractive target for novel therapies.